BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 18316592)

  • 1. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth.
    Ohta T; Iijima K; Miyamoto M; Nakahara I; Tanaka H; Ohtsuji M; Suzuki T; Kobayashi A; Yokota J; Sakiyama T; Shibata T; Yamamoto M; Hirohashi S
    Cancer Res; 2008 Mar; 68(5):1303-9. PubMed ID: 18316592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
    Uruno A; Motohashi H
    Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
    Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
    PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.
    Taguchi K; Motohashi H; Yamamoto M
    Genes Cells; 2011 Feb; 16(2):123-40. PubMed ID: 21251164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis.
    Yang JJ; Tao H; Hu W; Liu LP; Shi KH; Deng ZY; Li J
    Cell Signal; 2014 Nov; 26(11):2381-9. PubMed ID: 25049078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the Keap1-Nrf2 pathway in cancer.
    Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
    Adv Cancer Res; 2014; 122():281-320. PubMed ID: 24974185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2.
    Sun Z; Zhang S; Chan JY; Zhang DD
    Mol Cell Biol; 2007 Sep; 27(18):6334-49. PubMed ID: 17636022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the negative regulator of Nrf2, Keap1: a historical overview.
    Itoh K; Mimura J; Yamamoto M
    Antioxid Redox Signal; 2010 Dec; 13(11):1665-78. PubMed ID: 20446768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo.
    Suzuki T; Maher J; Yamamoto M
    Cancer Res; 2011 Mar; 71(5):1700-9. PubMed ID: 21177379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer.
    Padmanabhan B; Tong KI; Ohta T; Nakamura Y; Scharlock M; Ohtsuji M; Kang MI; Kobayashi A; Yokoyama S; Yamamoto M
    Mol Cell; 2006 Mar; 21(5):689-700. PubMed ID: 16507366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular effects of cancer-associated somatic mutations on the structural and target recognition properties of Keap1.
    Khan H; Killoran RC; Brickenden A; Fan J; Yang D; Choy WY
    Biochem J; 2015 Apr; 467(1):141-51. PubMed ID: 25582950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
    Shibata T; Ohta T; Tong KI; Kokubu A; Odogawa R; Tsuta K; Asamura H; Yamamoto M; Hirohashi S
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13568-73. PubMed ID: 18757741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of the Keap1-Nrf2 pathway in cancer.
    Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
    Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the Keap1 gene inactivates its function, promotes Nrf2 nuclear accumulation, and is involved in arsenite-induced human keratinocyte transformation.
    Wang D; Ma Y; Yang X; Xu X; Zhao Y; Zhu Z; Wang X; Deng H; Li C; Gao F; Tong J; Yamanaka K; An Y
    Free Radic Biol Med; 2015 Dec; 89():209-19. PubMed ID: 26409248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
    Hayes JD; McMahon M
    Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
    Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
    Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.
    Kim YJ; Ahn JY; Liang P; Ip C; Zhang Y; Park YM
    Cancer Res; 2007 Jan; 67(2):546-54. PubMed ID: 17234762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.